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Abstract
Background: Inflammation and pain associated with temporomandibular joint disorder, a chronic disease that
affects 15% of the adult population, involves activation of trigeminal ganglion nerves and development of
peripheral and central sensitization. Natural products represent an underutilized resource in the pursuit of safe and
effective ways to treat chronic inflammatory diseases. The goal of this study was to investigate effects of grape
seed extract on neurons and glia in trigeminal ganglia and trigeminal nucleus caudalis in response to persistent
temporomandibular joint inflammation. Sprague Dawley rats were pretreated with 200 mg/kg/d MegaNatural-BP
grape seed extract for 14 days prior to bilateral injections of complete Freund’s adjuvant into the
temporomandibular joint capsule.
Results: In response to grape seed extract, basal expression of mitogen-activated protein kinase phosphatase 1
was elevated in neurons and glia in trigeminal ganglia and trigeminal nucleus caudalis, and expression of the
glutamate aspartate transporter was increased in spinal glia. Rats on a normal diet injected with adjuvant exhibited
greater basal levels of phosphorylated-p38 in trigeminal ganglia neurons and spinal neurons and microglia.
Similarly, immunoreactive levels of OX-42 in microglia and glial fibrillary acidic protein in astrocytes were greatly
increased in response to adjuvant. However, adjuvant-stimulated levels of phosphorylated-p38, OX-42, and glial
fibrillary acidic protein were significantly repressed in extract treated animals. Furthermore, grape seed extract
suppressed basal expression of the neuropeptide calcitonin gene-related peptide in spinal neurons.
Conclusions: Results from our study provide evidence that grape seed extract may be beneficial as a natural
therapeutic option for temporomandibular joint disorders by suppressing development of peripheral and central
sensitization.
Background
Temporomandibular joint disorder (TMJD) is a chronic
disease that affects 15% of the adult population and is
characterized by pain in the muscles and joint associated
with mastication [1,2]. TMJD affects both men and
women equally with the incidence of TMJD-related pain
highest during adolescence age [3]. TMJD pathology
involves activation of trigeminal ganglia nerves that pro-
vide sensory innervation to the muscles and joint and
function to relay nociceptive signals to the trigeminal
nucleus caudalis (TNC) [4,5]. In addition, development of
peripheral and central sensitization, which are mediated
by increased neuron-glia interactions, are implicated in
TMJD pathology [6-8]. While peripheral sensitization of
trigeminal nociceptive neurons involves satellite glial cells
within the trigeminal ganglia, initiation and maintenance
of central sensitization and persistent pain are facilitated
by spinal astrocytes and microglia [9,10]. These glial cells
modulate neuronal excitability by regulating the extracel-
lular environment around neurons via the uptake of K
+
ions and glutamate by selective transporters [11,12].
Mitogen-activated protein (MAP) kinases, which are a
family of signal transduction enzymes activated in
response to inflammatory stimuli, play an important
role in the development of peripheral and central sensi-
tization [13-15]. The MAP kinase p38 is reported to
mediate sensitization of primary and second order
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sion and activity, membrane receptor expression, and
stimulating synthesis and secretion of cytokines that
promote and maintain a hyperexcitable state of neurons
[15-17]. Another protein implicated in the initiation of
peripheral and central sensitization is the MAP kinase-
responsive neuropeptide calcitonin gene-related peptide
(CGRP) [18]. CGRP is known to stimulate glial cells in
the trigeminal ganglia and TNC to release cytokines and
other inflammatory molecules leading to a lower thresh-
old of activation and contributing to persistent pain
[19-21]. The stimulatory effects of CGRP are reported
to involve upregulation of MAP kinases in neurons and
glia [22-24]. In addition, CGRP promotes development
of central sensitization by increasing the activity of glu-
tamate receptors expressed on second order neurons
that facilitate pain transmission [25,26].
The activity of MAP kinases is regulated by a family of
proteins known as MAP kinase phosphatases (MKP)
[27,28]. Expressions of MKPs, which are induced in
response to inflammatory stimuli, function in a compen-
satory manner to restore normal levels of active MAP
kinases. For example, MKP-1 is reported to preferen-
tially suppress active, phosphorylated p38 levels in
response to inflammatory stimuli or nerve injury [29].
Importantly, data from recent studies provide evidence
that mice lacking the MKP-1 gene have elevated MAP
kinase activity [30], increased cytokine-induced inflam-
mation [29], and higher susceptibility to inflammatory
injuries [31,32]. Thus, MKPs play an important role in
modulating nociceptive responses to inflammatory sti-
muli and restoring cellular homeostasis [33].
Chronic pathological pain, which is characteristic of
TMJD, is clinically difficult to treat using standard phar-
macological therapies. However, natural products offer a
novel method for preventing and treating chronic dis-
eases [34,35]. In particular, results from a recent study
provided evidence that including a polyphenol enriched
grape seed extract (GSE) in the diet of mice significantly
attenuated cognitive deterioration and Ab oligomeriza-
tion in neurons in a model of Alzheimer’sd i s e a s e[ 3 6 ] .
The goal of our study was to investigate the effect of
GSE as a dietary supplement on proteins in neurons
and glia in trigeminal ganglia and TNC under basal con-
ditions and in response to chronic inflammation of the
temporomandibular joint (TMJ) induced by injection of
complete Freund’s adjuvant (CFA) in the joint capsule.
Results
Expression of MKP-1 in trigeminal ganglia is increased in
response to GSE treatment
Initially, trigeminal ganglia from unstimulated control
rats were isolated and longitudinal sections of the entire
ganglia were co-stained with antibodies directed against
NeuN and Kir 4.1, and the fluorescent nuclear dye
DAPI. NeuN protein staining was observed in the cyto-
sol and nucleus of neuronal cell bodies in the trigeminal
ganglion, while Kir 4.1 staining was localized to the cyto-
sol of satellite glial cells (Figure 1A). In trigeminal gang-
lia, numerous functional units consisting of a single
neuronal cell body surrounded by satellite glia cells were
visible throughout the mandibular (V3) region.
The cellular expression of the MAP kinase phospha-
tase MKP-1 in trigeminal ganglia obtained from animals
drinking tap water (naïve control) or water supplemen-
ted with GSE was investigated by immunohistochemis-
try. In control animals, MKP-1 staining was primarily
observed in the cytosol and nucleus of satellite glial
cells, with staining barely visible in neurons (Figure 1B).
However, the intensity of MKP-1 staining was greatly
increased in the nucleus of neurons, and cytosol of
satellite glial cells in animals treated with 200 mg/kg/d
GSE. Animals treated with GSE had a significant
increase in the staining intensity for MKP-1 (1.65 ±
0.12, P < 0.01) when compared to control animals
(1.00 ± 0.09) (Figure 1C). Importantly, there were no
appreciable changes in weight, eating/drinking habits, or
grooming behavior in animals receiving GSE when com-
pared to control animals (data not shown).
GSE repressed CFA-stimulated P-p38 expression in
trigeminal ganglia neurons
Expression of the active, phosphorylated form of p38
(P-p38) was barely visible in neurons or glia in ganglia
obtained from control animals (Figure 2A). A similar
staining pattern was observed in animals treated with GSE
alone. In contrast, animals that received injections of
50 μL of CFA into their joint capsules had greatly
increased nuclear and cytosolic P-p38 staining in neurons
located in the V3 region of the ganglia seven days post
injection. Importantly, a marked decrease in neuronal
P-p38 expression to basal levels was seen in animals pre-
treated with GSE prior to injection of CFA. There was no
n o t i c e a b l ed i f f e r e n c ei nt h es t a i n i n gi n t e n s i t yo fg a n g l i a
obtained from animals treated with GSE alone (0.92 ± 0.13)
when compared to control animals (1.00 ± 0.10). In con-
trast, a significant increase in staining intensity (2.39 ± 0.17,
P < 0.01) was seen in response to CFA injection. However,
rats pretreated with GSE prior to CFA injection had only a
minor increase in staining intensity (1.03 ± 0.15) that was
similar to control animals and significantly lower (P <0 . 0 1 )
than animals with CFA injections (Figure 2B).
GSE regulation of CGRP, MKP-1, and GLAST expression in
the TNC
Initially, spinal cord from unstimulated animals was trans-
versely sectioned 4-5 mm from the obex and stained with
DAPI to identify the nuclei of neurons and glia in the TNC
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Page 2 of 12region (Figure 3A, A’). In unstimulated control animals,
CGRP staining was readily detected in neurons located in
discrete bands within the dorsal horn of the spinal cord,
including the TNC region. However, the expression of
CGRP in animals consuming GSE was greatly decreased
when compared to control levels (Figures 3B and 3C).
Inclusion of GSE in the water caused a significant decrease
in CGRP staining intensity (0.56 ± 0.04, P < 0.01) when
compared to control animals (1.00 ± 0.05) (Figure 3D).
The effect of GSE on basal MKP-1 expression in the
TNC was similar to that observed in trigeminal ganglia.
While the level of MKP-1 was barely detectable in neu-
rons, astrocytes, and microglia in control animals, MKP-
1 expression was greatly increased throughout the TNC
in neurons and glia in response to GSE (Figure 4A).
When compared to control animals (1.00 ± 0.10), GSE
treated animals exhibited a significant increase in stain-
ing intensity (3.15 ± 0.16, P < 0.01) (Figure 4B).
A similar stimulatory effect was seen in the expression
of the glial cell glutamate uptake transporter, GLAST, in
the TNC of animals on a GSE supplemented diet. While
GLAST staining was present in glia within the TNC in
control animals, GLAST expression was greatly
increased in glial cells throughout the TNC in animals
treated with GSE (Figure 5A). When compared to con-
trol animals (1.00 ± 0.06), GSE treated animals exhibited
a significant increase in staining intensity in glial cells
(2.25 ± 0.11, P < 0.01) (Figure 5B).
GSE repressed CFA-mediated expression of P-p38, GFAP
and OX-42 in the TNC
Minimal expression of P-p38 was detected in neurons
and glia within the TNC obtained from control animals
Figure 1 Basal MPK-1 expression is increased in both neurons
and satellite glia cells after GSE treatment. (A) An image from a
longitudinal section of trigeminal ganglia costained with the neuronal
cell marker NeuN, the glial cell marker Kir4.1, or the nuclear dye DAPI is
shown. The bottom right image shows a merged image of NeuN, Kir 4.1
and DAPI staining. Thick horizontal arrows identify the cell bodies of
neurons while thin vertical arrows indicate satellite glia cells. (B) Sections
of the posterolateral portion of the ganglion (V3) were obtained from
untreated animals (CON) or animals treated with GSE for 14 days (GSE).
Images of neuron-satellite glial cell enriched regions stained for MKP-1
are shown in the top panels. The bottom panels represent the same
section costained for MKP-1 and DAPI. (C) The average fold change ±
SEM of MKP-1 staining intensity from control values, which were made
equal to one, is reported (n = 3 independent experiments) * P <0 . 0 1
when compared to control. Magnification bar = 50 μm.
Figure 2 Increased P-p38 expression in trigeminal ganglia
neurons in response to CFA is repressed in rats on a GSE
supplemented diet. Sections of the posterolateral portion of the
ganglion (V3) were obtained from untreated animals (CON), GSE
treated animals (GSE), animals injected with CFA (CFA), or treated
with GSE prior to injection of CFA (GSE + CFA). (A) Images of neuron-
satellite glial regions stained for P-p38 are shown in the top panels.
The bottom panels are the same sections co-stained for P-p38 and
DAPI. (B) The average fold change ± SEM of P-p38 staining intensity
from control values is reported (n = 3 independent experiments)
* P < 0.01 when compared to control levels, while
# P < 0.01 when
compared to CFA stimulated levels. Magnification bar = 50 μm.
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Page 3 of 12Figure 3 GSE suppresses basal CGRP expression in the TNC. (A) An image (40×) of a section of spinal cord 4 mm from the obex stained
with the nuclear dye DAPI is shown. (A’) An enlarged image of the area of spinal cord that contains the TNC (yellow box in A). (B) Sections of
spinal cord obtained from untreated animals (CON) or treated with GSE for 14 days (GSE) and stained for CGRP are shown in the top panels
(200×). The bottom panels represent a merged image of the same sections co-stained with CGRP and DAPI. (C) The top panels show images
(400×) of TNC stained with antibodies against CGRP. The bottom panels represent the same sections stained for CGRP and DAPI. (D) The
average fold change ± SEM of CGRP staining intensity from control values, which were made equal to one, is reported (n = 3 independent
experiments) * P < 0.01 when compared to control. Magnification bar = 50 μm.
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treated with GSE alone. In contrast, P-p38 expression
was greatly increased in neurons and glia in the TNC in
response to prolonged TMJ inflammation caused by
injection of CFA into the joint capsule. However, levels
of P-p38 were greatly repressed to near basal levels in
animals receiving GSE supplemented in their water
prior to CFA injection. To identify the cell types exhibit-
ing increased P-p38 expression, tissues were costained
with antibodies directed against the neuronal protein
NeuN, the microglial protein Iba1, or an astrocyte mar-
ker glial fibrillary acidic protein (GFAP). Based on our
costaining results, elevated levels of P-p38 were only
observed in neurons and microglia (data not shown).
There was no significant difference in the staining inten-
sity in animals treated with GSE alone (1.12 ± 0.09)
when compared to levels in control animals (1.00 ±
0.06) (Figure 6B). In contrast, CFA treatment caused a
significant increase in P-p38 staining intensity (2.68 ±
0.20, P < 0.01) that was greatly repressed in animals
receiving GSE (1.42 ± 0.09, P < 0.01).
The effect of CFA and GSE on microglia within the
TNC was investigated using antibodies directed against
OX-42, a marker of microglia activation. In tissues from
control or GSE treated animals, low level expression of
OX-42 was observed in microglia (Figure 7A). However,
OX-42 expression was greatly increased in microglia in
the TNC seven days after CFA injection into the joint
capsule. In contrast, animals pretreated with GSE before
CFA injection exhibited much lower levels of OX-42
expression when compared to animals that received
CFA injections alone. There was no significant differ-
ence in the staining intensity of GSE treated animals
Figure 4 GSE increases basal MKP-1 expression in neurons and
glia in the TNC. Sections of spinal cord were obtained from
untreated animals (CON) or animals treated with GSE (GSE). (A)
Images of a section of spinal cord stained for MKP-1 are shown in
the top panels. The bottom panels represent the same sections co-
stained with MKP-1 and DAPI. (B) The average fold change ± SEM
of MKP-1 staining intensity from control values is reported (n = 3
independent experiments) * P < 0.01 when compared to control
levels. Magnification bar = 50 μm.
Figure 5 Basal expression of GLAST is increased in glial cells in
the TNC in response to GSE. Sections of spinal cord were
obtained from untreated animals (CON) and GSE treated animals
(GSE). (A) Images of spinal cord sections stained for GLAST are
shown in the top panels. The bottom panels represent the same
sections co-stained with GLAST and DAPI. (B) The average fold
change ± SEM of GLAST staining intensity from control values is
reported (n = 3 independent experiments) * P < 0.01 when
compared to control levels. Magnification bar = 50 μm.
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mals (1.00 ± 0.05) (Figure 7B). In contrast, CFA injec-
tion resulted in a significant increase in staining
intensity (2.62 ± 0.15, P < 0.01) that was repressed in
animals pretreated with GSE prior to CFA injections
(1.51 ± 0.10, P < 0.01).
Low level expression of GFAP, a marker of activated
astrocytes, was observed in numerous astrocytes in the
TNC from control animals and those treated with GSE
(Figure 8A). In contrast, GFAP expression was greatly
increased in response to CFA injections. However, the
stimulatory effect of CFA on GFAP expression was
greatly repressed in animals receiving with GSE prior to
CFA. There was no significant difference in the staining
intensity of rats treated with GSE (0.98 ± 0.06) when
compared to control animals (1.00 ± 0.08) (Figure 8B).
In contrast, CFA caused a significant increase in staining
intensity (1.76 ± 0.06, P < 0.01) over levels in control
and GSE treated animals. The stimulatory effect of CFA
on GFAP levels was significantly repressed in animals
on a GSE supplemented diet (0.97 ± 0.07, P < 0.01).
Discussion
In this study, we initially investigated cellular changes in
trigeminal neurons and glia in response to GSE supple-
mented diets. We chose to study the effect of MegaNa-
tural-BP GSE, a highly purified extract from Vitis vinifera
seeds containing >90% polyphenols as gallic acid equiva-
lents [36]. Inclusion of this product in the diet of mice
was reported to significantly attenuate cognitive dete-
rioration and Ab oligomerization. Importantly, the con-
centration of GSE shown to cause changes in Ab
oligomerization was identical to the amount used in our
study and shown to suppress inflammatory responses
caused by prolonged stimulation of trigeminal nerves.
GSE supplemented diets significantly increased the basal
Figure 6 GSE represses CFA stimulated P-p38 expression in TNC neurons and glial cells. Sections of spinal cord were obtained from
untreated animals (CON), animals treated with GSE (GSE), animals injected with CFA (CFA), or animals pretreated with GSE prior to an injection
with CFA (GSE + CFA). (A) Images of sections of the TNC stained for P-p38 are shown in the top panels. The bottom panels represent the same
sections co-stained P-p38 and DAPI. (B) The average fold change ± SEM of P-p38 staining intensity from control values is reported (n = 3
independent experiments) * P < 0.01 when compared to control levels while
# P < 0.01 when compared to CFA stimulation. Magnification
bar = 50 μm.
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trigeminal ganglia, as well as in neurons and glia in the
TNC. MKP-1 is reported to dephosphorylate, and there-
fore, inactivate several MAP kinases including p38, JNK,
and ERK, in a concentration dependent manner [33].
Thus, increased expression of MKP-1 in trigeminal gang-
lia and the TNC would function to control MAP kinase
activity in response to trigeminal nerve activation. In sup-
port of this notion, we found that CFA stimulated levels
of active p38 in trigeminal ganglia and TNC were signifi-
cantly repressed in animals receiving GSE when com-
pared to control animals. Importantly, MAP kinases such
as p38, are implicated in peripheral and central sensitiza-
tion, and blocking MAP kinases with specific inhibitors is
reported to suppress nociceptive responses and sensitiza-
tion [15,37,38]. To our knowledge, this is the first study
to provide evidence that GSE can lead to sustained, ele-
vated levels of MKP-1, an enzyme that plays a fundamen-
tal role in regulating the activity of MAP kinases and
thus, controlling development of peripheral and central
sensitization.
Our finding that natural products such as GSE
increases MKP-1 expression is in agreement with our
previous result that demonstrated animals fed an
enriched diet containing 1% or 10% cocoa exhibited ele-
vated levels of MKP-1 [39]. Interestingly, the anti-
inflammatory effects of dexamethasone have been
shown to be meditated, at least to some degree, by indu-
cing a sustained expression of MKP-1 [40]. Furthermore,
the anti-nociceptive effects of opioids are reported to
involve increased expression of MKP-1 [41]. Thus, it
appears that daily consumption of GSE or cocoa may
function to block inflammatory and nociceptive
responses in the trigeminal ganglion by a similar cellular
mechanism as has been reported for glucocorticoids and
opioids.
Another interesting finding from our study was that
dietary GSE decreases basal expression of the MAP
Figure 7 GSE treatment represses CFA stimulated OX-42 expression in microglia. Sections of spinal cord were obtained from untreated
animals (CON), GSE treated animals (GSE), animals injected with CFA (CFA), or animals pretreated with GSE prior to an injection of CFA (GSE +
CFA). (A) Images of spinal cord sections stained for OX-42 are shown in the top panels. The bottom panels represent the same sections co-
stained with OX-42 and DAPI. (B) The average fold change ± SEM of OX-42 staining intensity from control values is reported (n = 3 independent
experiments) * P < 0.01 when compared to control levels, while
# P < 0.01 compared to CFA stimulation. Magnification bar = 50 μm.
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sion of GLAST in the TNC. CGRP is a multifunctional
neuropeptide known to promote inflammatory and noci-
ceptive responses and is implicated in TMJ pathology
[18]. In response to trigeminal neuron activation, per-
ipheral CGRP release promotes an inflammatory
response within the joint capsule, while central release
of CGRP mediates enhanced nociception and central
sensitization. CGRP is thought to contribute to nocicep-
tion and central sensitization by its stimulatory effects
on second order neurons and glia within the TNC
[42,43]. For example, CGRP release causes upregulation
of a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
(AMPA) receptor proteins [44], prolongs activity of sub-
stance P by preventing its degradation [45], and
increases levels of the purinegic receptor P2X3 [46]. In
addition, CGRP via activation of protein kinase A (PKA)
is proposed to modulate activity of (N-methyl-D-aspartic
acid) NMDA receptors thereby regulating glutamate
excitation of second order nociceptive neurons [25].
Thus, decreased levels of CGRP are likely to reduce the
stimulatory effects of glutamate, substance P, and ATP
on second order neurons that promote nociception
[25,47]. Significantly, we also found that GSE caused
increased expression of the glutamate transporter
GLAST that functions to regulate the amount of extra-
cellular glutamate. Sustained GLAST expression in
astrocytes leads to reduced glutamate levels, thus
decreasing the excitability state of neurons and minimiz-
ing spontaneous activation [48]. To our knowledge, this
is the first example of using natural products as dietary
supplements to increase GLAST expression. Taken
together, our findings provide evidence that GSE func-
tions to regulate levels of proteins known to play
Figure 8 GSE represses stimulated GFAP expression in astrocytes in response to CFA. Sections of spinal cord were obtained from
untreated animals (CON), GSE treated animals (GSE), animals injected with CFA (CFA), or animals pretreated with GSE prior to an injection of
CFA (GSE + CFA). (A) Images of spinal cord sections stained for GFAP are shown in the top panels. The bottom panels represent the same
sections co-stained with GFAP and DAPI. (B) The average fold change ± SEM of GFAP staining intensity from control values is reported (n = 3
independent experiments) * P < 0.01 when compared to control levels, while
# P < 0.01 compared to CFA stimulation. Magnification
bar = 50 μm.
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excitability by decreasing CGRP expression and increas-
ing GLAST expression.
In our study, we observed increased expression of P-p38
in trigeminal ganglia neurons, and neurons and microglia
in the TNC in response to CFA injection. Increased levels
of P-p38 are thought to contribute to the development of
peripheral and central sensitization [10,16], a process char-
acteristic of TMJ pathology, by increasing the synthesis
and release of proinflammatory cytokines [49,50]. Chronic
stimulation by CFA is a well-established model for TMJ
pathology and when injected into the joint capsule results
in a long-lasting inflammatory event and prolonged activa-
tion of nociceptive neurons [9,51,52]. Importantly, we
found that the stimulatory effects of CFA on P-p38
expression in trigeminal ganglia and TNC were signifi-
cantly repressed in animals receiving GSE. We propose
that the basal increase in MKP-1 mediated by dietary GSE
is responsible, at least in part, for the repressed expression
of P-p38 in trigeminal ganglia and TNC neurons and glia
in response to CFA since MKP-1 is a primary regulator of
p38 activity [33]. Taken together, GSE repression of P-p38
is likely to prevent development of a persistent pain state
in response to CFA, which is used as a model of TMJ
pathology.
We found that bilateral injection of CFA caused
enhanced activity of astrocytes and microglia and that
pretreatment with GSE was sufficient to repress the sti-
mulatory effect of CFA on these glial cells. Our results
with respect to CFA are in agreement with previous stu-
dies that reported the inflammatory response to CFA
injection increased activation of astrocytes and micro-
glia, as demonstrated by increases in the expression of
GFAP and OX-42, respectively [5,9,53]. While once
t h o u g h tt op l a ym a i n l yas u p p o r t i v er o l ef o rn e u r o n s ,i t
is now known that astrocytes and microglia modulate
the activation state of neurons and contribute to hyper-
sensitivity and the chronification of pain states [54].
Under normal conditions, both microglia and astrocytes
are relatively quiescent. However, in response to nox-
ious/inflammatory stimuli these cells release proinflam-
matory cytokines leading to activation of nearby
neurons and other glia [55,56]. Interestingly, GSE is able
to repress the stimulatory effects of CFA in both astro-
cytes and microglia as demonstrated by reduced levels
of GFAP, a structural protein and a marker of astrocyte
activation, and OX-42, a marker of activated microglia
[57,58]. Enhanced cellular activity of both astrocytes and
microglia in the trigeminal system have been implicated
in the development of persistent pain states [59]. Thus,
it appears that GSE functions to modulate cellular
responses to inflammatory stimuli by inhibiting glial cell
activation, which in turn, would decrease the excitability
state of nociceptive neurons in the TNC.
Conclusions
In summary, GSE elevated expression of proteins in tri-
geminal ganglia and TNC known to decrease neuronal
excitability and suppressed CFA-induced expression of
several proteins implicated in peripheral and central
sensitization. Although not investigated in our study,
inclusion of dietary GSE would likely also suppress
CFA-mediated nocifensive behaviors, including mechan-
ical allodynia and thermal hyperalgesia, which are char-
acteristic of the development of central sensitization.
Thus, based on our cellular findings and results from
behavioral studies on CFA-induced inflammation in the
TMJ or masseter muscle [60,61], we propose that
dietary GSE will be therapeutically beneficial for redu-




All animal studies were approved by the Institutional
Animal Care and Use Committee at Missouri State Uni-
versity and were conducted in compliance with all
established guidelines in the Animal Welfare Act and
National Institutes of Health. A concerted effort was
made to reduce the number of animals used and to
minimize any suffering. Adult male Sprague-Dawley rats
(200-230 g), Charles River Laboratories, Wilmington,
MA) had unrestricted access to food and water and
were kept on a 12-hour light/dark cycle. Changes in
food and water consumption as well as weight and
grooming behaviors were monitored and recorded daily
to assess the overall health of the animals. Rats were
placed into two groups with one group of rats receiving
a normal diet while the other group received a normal
diet supplemented with 200 mg/kg/d MegaNatural-BP
Grape Seed Polyphenol Extract (GSE, Healthy Origins,
Pittsburgh, PA) dissolved in their drinking water. This
amount is equivalent to a human dose of 1 g/d using
the Food and Drug Administration criteria for convert-
ing drug equivalent dosages across species [36]. Drink-
ing water for all animals was changed every two days.
Chronic model of TMJ inflammation
Rats were anesthetized by inhalation of 3.5% isoflurane
(VetEquip, Pleasanton, CA). After fourteen days of
drinking normal water or GSE supplemented water,
some rats received an injection of 50 μLc o m p l e t e
Freund’s adjuvant (CFA; Sigma-Aldrich, St. Louis, MO)
in each TMJ capsule. All animals then continued their
assigned diets for seven more days before being sacri-
ficed. The time of treatment, preparation, and amount
of stimulatory agent were based on results from pre-
vious studies in our laboratory [39,62]. As controls,
some animals were not injected (naïve control).
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Trigeminal ganglia and spinal cord encompassing the
spinomedullary junction (Vc/C1) transition zone con-
taining the TNC, were removed from all rats following
CO2 asphyxiation and placed in a solution of 4% paraf-
ormaldehyde overnight. Following paraformaldehyde
fixation, tissues were incubated in 15% sucrose in dis-
tilled water at 4°C for 1 hour and then 30% sucrose
overnight at 4°C. Trigeminal ganglia and spinal cord tis-
sues were then placed dorsal side up on a slide, covered
with OCT Compound (Sakura Finetek, Torrance, CA)
and quickly frozen. Fourteen-micron longitudinal sec-
tions of the entire trigeminal ganglion tissue were seri-
ally prepared using a cryostat (Microm HM 525,
Thermo Scientific, Waltham, MA) set at -20°C. Spinal
cord sections (20 μm) containing the TNC were sec-
tioned transversely at a distance of 4-5 mm posterior to
the obex using a cryostat set at -18°C. All sections were
mounted on Superfrost Plus microscope slides (Fisher
Scientific, Pittsburg, PA). Each slide used for immuno-
histochemistry contained one section from each experi-
mental condition.
Immunohistochemistry
Slides containing either sectioned ganglia or spinal cord
were incubated in a solution of 0.1% Triton X-100 and
5% donkey serum (Jackson Immuno Reasearch Labora-
tories, West Grove, PA) for 30 minutes. Next, sections
were incubated overnight at 4°C with rabbit polyclonal
antibodies directed against the phosphorylated, active
MAP kinase protein P-p38 (1:200 in 5% donkey serum/
PBS, Cell Signaling, Beverly, MA), MKP-1 (1:500,
Upstate Cell Signaling Solutions, Lake Placid, NY),
CGRP (1:1000, Sigma-Aldrich), Kir 4.1 (1:1000, Alomone
Labs, Jerusalem, Israel), or GLAST (1:200, Abcam, Cam-
b r i d g e ,M A ) .I na d d i t i o n ,s o m es e c t i o n sw e r ei n c u b a t e d
for three hours at room temperature with either mouse
monoclonal antibodies against NeuN (1:500, Millipore,
Billerica, MA), OX-42 (1:200, Abcam), or GFAP (1:500,
Millipore), or a goat polyclonal antibody against Iba1
(1:300, Abcam). Sections were next incubated for one
hour at room temperature with either Alexa Fluor 594
donkey anti-rabbit (P-p38, MKP-1, CGRP, Kir 4.1,
GLAST), Alexa Fluor 594 donkey anti-mouse (OX-42,
GFAP), Alexa Fluor 488 donkey anti-mouse (NeuN), or
Alexa Fluor 488 donkey anti-goat (Iba1) IgG antibodies
(diluted 1:500 in PBS, Invitrogen, Carlsbad, CA) to
detect immunofluorescent proteins by UV-fluorescence
microscopy. Sections were mounted using Vectashield
medium (H-1200) containing 4’,6-diamidino-2-phenylin-
dole (DAPI; Vector Laboratories, Burlingame, CA) to
co-stain cell nuclei. Images (40×, 200×, and 400×) were
collected using a Zeiss Axiocam mRm camera mounted
on a Zeiss Imager Z1 fluorescent microscope equipped
with an ApoTome. Image acquisition was performed
using Zeiss AxioVision (Rel 4.7, Thornwood, NY).
Measurement of cell counts and staining intensity
Images containing the mandibular branch (V3) of the
middle portion of the trigeminal ganglion or regions of
spinal cord tissue containing the TNC were used for
analysis. Four randomly chosen 400× images containing
a similar number of cells as identified by DAPI, were
analyzed for each experimental condition, which were
repeated in three independent experiments, resulting in
12 images for the intensity measurements. The relative
staining intensity measurements were based on our pre-
viously published protocols [39,63]. Two researchers
blinded to the experimental conditions performed the
measurements. For images from trigeminal ganglia, the
mean gray intensity of four circular regions from areas
containing a single neuron and associated surrounding
satellite glial cell were measured and the mean gray
intensity from an area containing only Schwann cells
and fiber tracts was subtracted as background. The
staining intensity in spinal cord tissue was determined
by measuring the mean gray intensity from four regions
of staining in the trigeminal nucleus caudalis and sub-
tracting the intensity from areas containing only back-
ground staining. The fold change in staining intensity
was defined as the mean change in relative intensity in
the experimental condition when compared to mean
levels of the unstimulated control tissue, which was set
equal to one. Statistical analysis was performed using
either one way ANOVA followed by post-hoc Tukey
test or Students T-test. Results were considered signifi-
cant when P < 0.05. All statistical tests were performed
using SPSS (Version 16, IBM, Chicago, IL).
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